News & Events

Presentation: Phase 2 randomized, double-blind, placebo-controlled study to evaluate BHB/HRS-1893 in adults with symptomatic non-obstructive hypertrophic cardiomyopathy

Virtual Fireside Chat

Presentation: Efficacy and Safety of BHB/HRS-1893 In Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From a 12-Week Phase 2 Study

Virtual Fireside Chat

Presentation: HRS-1893, a cardiac myosin inhibitor, in patients with obstructive hypertrophic cardiomyopathy